{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:06:47Z","timestamp":1793498807280,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/mp.2016.3","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T04:39:32Z","timestamp":1456202372000},"page":"1696-1709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1610,"title":["A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression"],"prefix":"10.1038","volume":"21","author":[{"given":"D R","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Rapaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"BFmp20163_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nn.3922","volume":"18","author":"Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium","year":"2015","unstructured":"Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 2015; 18: 199\u2013209.","journal-title":"Nat Neurosci"},{"key":"BFmp20163_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421\u2013427.","journal-title":"Nature"},{"key":"BFmp20163_CR3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","volume":"460","author":"SM Purcell","year":"2009","unstructured":"The International Schizophrenia Consortium Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia that overlaps with bipolar disorder. Nature 2009; 460: 748\u2013752.","journal-title":"Nature"},{"key":"BFmp20163_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000356539","volume":"21","author":"IG Barbosa","year":"2014","unstructured":"Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL . The immunology of bipolar disorder. Neuroimmunomodulation 2014; 21: 117\u2013122.","journal-title":"Neuroimmunomodulation"},{"key":"BFmp20163_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.schres.2013.07.029","volume":"150","author":"A Ezeoke","year":"2013","unstructured":"Ezeoke A, Mellor A, Buckley P, Miller BJ . A systematic quantitative review of blood autoantibody elevations in schizophrenia. Schizophr Res 2013; 150: 245\u2013251.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR6","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s11481-013-9462-8","volume":"8","author":"SM Gibney","year":"2013","unstructured":"Gibney SM, Drexhage HA . Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol 2013; 8: 900\u2013920.","journal-title":"J Neuroimmune Pharmacol"},{"key":"BFmp20163_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","volume":"73","author":"B Miller","year":"2013","unstructured":"Miller B, Gassama B, Sebastian D, Buckley P, Mellor A . Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2013; 73: 993\u2013999.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000356540","volume":"21","author":"N M\u00fcller","year":"2014","unstructured":"M\u00fcller N . Immunology of major depression. Neuroimmunomodulation 2014; 21: 123\u2013130.","journal-title":"Neuroimmunomodulation"},{"key":"BFmp20163_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.schres.2014.05.001","volume":"157","author":"DM Pearlman","year":"2014","unstructured":"Pearlman DM, Najjar S . Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res 2014; 157: 249\u2013258.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2014.12.015","volume":"174","author":"Z Ayorech","year":"2015","unstructured":"Ayorech Z, Tracy DK, Baumeister D, Giaroli G . Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord 2015; 174: 467\u2013478.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O K\u00f6hler","year":"2014","unstructured":"K\u00f6hler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381\u20131391.","journal-title":"JAMA Psychiatry"},{"key":"BFmp20163_CR12","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","volume":"39","author":"M Nitta","year":"2013","unstructured":"Nitta M, Kishimoto T, M\u00fcller N, Weiser M, Davidson M, Kane JM et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013; 39: 1230\u20131241.","journal-title":"Schizophr Bull"},{"key":"BFmp20163_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"IE Sommer","year":"2014","unstructured":"Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS . Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40: 181\u2013191.","journal-title":"Schizophr Bull"},{"key":"BFmp20163_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446\u2013457.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jad.2011.08.003","volume":"139","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ho RCM, Mak A . Interleukin (IL)-6, tumor necrosis factor alpha (TNF-\u03b1) and solubleinterleukin-2 receptors (sIL-2\u2009R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012; 139: 230\u2013239.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B . Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663\u2013671.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biopsych.2013.01.007","volume":"74","author":"A Modabbernia","year":"2013","unstructured":"Modabbernia A, Taslimi S, Brietzke E, Ashrafi M . Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 15\u201325.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jad.2012.06.010","volume":"144","author":"K Munkholm","year":"2013","unstructured":"Munkholm K, Vinberg M, Kessing LV . Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144: 16\u201327.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","volume":"63","author":"S Potvin","year":"2008","unstructured":"Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E . Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801\u2013808.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","volume":"155","author":"R Upthegrove","year":"2014","unstructured":"Upthegrove R, Manzanares-Teson N, Barnes NM . Cytokine function in medication-na\u00efve first episode psychosis: a systematic review and meta-analysis. Schizophr Resh 2014; 155: 101\u2013108.","journal-title":"Schizophr Resh"},{"key":"BFmp20163_CR21","doi-asserted-by":"publisher","first-page":"421746","DOI":"10.1155\/2015\/421746","volume":"2015","author":"R Florencio-Silva","year":"2015","unstructured":"Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS . Biology of bone tissue: structure, function, and factors that influence bone cells. BioMed Res Int 2015; 2015: 421746.","journal-title":"BioMed Res Int"},{"key":"BFmp20163_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cytogfr.2009.05.003","volume":"20","author":"WV Ingman","year":"2009","unstructured":"Ingman WV, Robertson SA . The essential roles of TGFB1 in reproduction. Cytokine Growth Factor Rev 2009; 20: 233\u2013239.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFmp20163_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","volume":"60","author":"PF Sullivan","year":"2003","unstructured":"Sullivan PF, Kendler KS, Neale MC . Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187\u20131192.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp20163_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0920-9964(98)00140-6","volume":"37","author":"K Akiyama","year":"1999","unstructured":"Akiyama K . Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999; 37: 97\u2013106.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jpsychires.2012.08.016","volume":"46","author":"M Borovcanin","year":"2012","unstructured":"Borovcanin M, Jovanovic I, Radosavljevic G, Dejanovic SD, Bankovic D, Arsenijevic N et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatric Res 2012; 46: 1421\u20131426.","journal-title":"J Psychiatric Res"},{"key":"BFmp20163_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.schres.2013.03.027","volume":"147","author":"M Borovcanin","year":"2013","unstructured":"Borovcanin M, Jovanovic I, Radosavljevic G, Dejanovic SD, Stefanovic V, Arsenijevic N et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res 2013; 147: 103\u2013109.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s11481-012-9382-z","volume":"7","author":"S-L Chen","year":"2012","unstructured":"Chen S-L, Lee S-Y, Chang Y-H, Chen S-H, Chu C-H, Tzeng N-S et al. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmun Pharmacol 2012; 7: 656\u2013664.","journal-title":"J Neuroimmun Pharmacol"},{"key":"BFmp20163_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.psychres.2006.08.005","volume":"158","author":"B Crespo-Facorro","year":"2008","unstructured":"Crespo-Facorro B, Carrasco-Mar\u00edn E, P\u00e9rez-Iglesias R, Pelayo-Ter\u00e1n JM, Fernandez-Prieto L, Leyva-Cobi\u00e1n F et al. Interleukin-12 plasma levels in drug-na\u00efve patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res 2008; 158: 206\u2013216.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","volume":"154","author":"L de Witte","year":"2014","unstructured":"de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS et al. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res 2014; 154: 23\u201329.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pnpbp.2014.01.001","volume":"51","author":"M Ding","year":"2014","unstructured":"Ding M, Song X, Zhao J, Gao J, Li X, Yang G et al. Activation of Th17 cells in drug na\u00efve, first episode schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry 2014; 51: 78\u201382.","journal-title":"Progr Neuro-Psychopharmacol Biol Psychiatry"},{"key":"BFmp20163_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbi.2012.06.010","volume":"31","author":"M Di Nicola","year":"2013","unstructured":"Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun 2013; 31: 90\u201395.","journal-title":"Brain Behav Immun"},{"key":"BFmp20163_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1017\/S1461145710001653","volume":"14","author":"RC Drexhage","year":"2011","unstructured":"Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA, van Beveren NJM et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 2011; 14: 746\u2013755.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFmp20163_CR33","first-page":"55","volume":"25","author":"B Dunjic-Kostic","year":"2013","unstructured":"Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A et al. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub 2013; 25: 55\u201361.","journal-title":"Psychiatr Danub"},{"key":"BFmp20163_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.psychres.2014.10.007","volume":"225","author":"Y El Kissi","year":"2015","unstructured":"El Kissi Y, Samoud S, Mtiraoui A, Letaief, Hannachi N, Ayachi M et al. Increased interleukin-17 and decreased BAFF serum levels in drug-free acute schizophrenia. Psychiatry Res 2015; 225: 58\u201363.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","volume":"194","author":"E Fernandez-Egea","year":"2009","unstructured":"Fernandez-Egea E, Bernardo M, Donner T, Congent I, Parellada E, Justicia A et al. Metabolic profile of antipsychotic-na\u00efve individuals with nonaffective psychosis. Br J Psychiatry 2009; 194: 434\u2013438.","journal-title":"Br J Psychiatry"},{"key":"BFmp20163_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/BF02900219","volume":"247","author":"UH Frommberger","year":"1997","unstructured":"Frommberger UH, Bauer J, Haselbauer P, Fr\u00e4ulin A, Riemann D, Berger M . Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228\u2013233.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFmp20163_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/archpsyc.1989.01810030098018","volume":"46","author":"R Ganguli","year":"1989","unstructured":"Ganguli R, Rabin BS . Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. Arch Gen Psychiatry 1989; 46: 292.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp20163_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-1781(94)90042-6","volume":"51","author":"R Ganguli","year":"1994","unstructured":"Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51: 1\u201310.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0920-9964(92)90006-Q","volume":"6","author":"WF Gattaz","year":"1992","unstructured":"Gattaz WF, Dalgalarrondo P, Schr\u00f6der HC . Abnormalities in serum concentrations of interleukin-2, interferon-\u03b1 and interferon-\u03b3 in schizophrenia not detected. Schizophr Res 1992; 6: 237\u2013241.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","volume":"33","author":"M Haack","year":"1999","unstructured":"Haack M, Hinze-Selch D, Fenzel T, Kraus T, K\u00fchn M, Schuld A et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407\u2013418.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR41","doi-asserted-by":"publisher","first-page":"e96021","DOI":"10.1371\/journal.pone.0096021","volume":"9","author":"SV Kalmady","year":"2014","unstructured":"Kalmady SV, Venkatasubramania G, Shivakumar V, Gautham S, Subramaniam A, Jose DA et al. Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-na\u00efve schizophrenia: evidence for differential susceptibility? PLoS One 2014; 9: e96021.","journal-title":"PLoS One"},{"key":"BFmp20163_CR42","first-page":"439","volume":"49","author":"T Kaminska","year":"2001","unstructured":"Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszen M . Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001; 49: 439\u2013445.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"BFmp20163_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","volume":"44","author":"YK Kim","year":"2000","unstructured":"Kim YK, Kim L, Lee MS . Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000; 44: 165\u2013175.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/00207450108986549","volume":"111","author":"DJ Kim","year":"2001","unstructured":"Kim DJ, Kim W, Yoon SJ, Go HJ, Choi BM, Jun TY et al. Effect of risperidone on serum cytokines. Int J Neurosci 2001; 111: 11\u201319.","journal-title":"Int J Neurosci"},{"key":"BFmp20163_CR45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/sj.mp.4001084","volume":"7","author":"YK Kim","year":"2002","unstructured":"Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs. Mol Psychiatry 2002; 7: 1107\u20131114.","journal-title":"Mol Psychiatry"},{"key":"BFmp20163_CR46","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.pnpbp.2004.05.047","volume":"28","author":"YK Kim","year":"2004","unstructured":"Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2004; 28: 1129\u20131134.","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20163_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000213565","volume":"59","author":"YK Kim","year":"2009","unstructured":"Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B . Cytokine changes and tryptophan metabolites in medication na\u00efve and medication-free schizophrenic patients. Neuropsychobiology 2009; 59: 123\u2013129.","journal-title":"Neuropsychobiology"},{"key":"BFmp20163_CR48","first-page":"153","volume":"24","author":"A Kubistova","year":"2012","unstructured":"Kubistova A, Joracek J, Novak T . Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012; 24: 153\u2013156.","journal-title":"Psychiatr Danub"},{"key":"BFmp20163_CR49","first-page":"375","volume":"34","author":"CC Lin","year":"2011","unstructured":"Lin CC, Chang MC, Chang PY, Huang TL . Increased interleukin-6 level in Taiwanese schizophrenic patients. Chang Gunng Med J 2011; 34: 375\u2013381.","journal-title":"Chang Gunng Med J"},{"key":"BFmp20163_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0920-9964(96)00029-1","volume":"21","author":"M Maes","year":"1996","unstructured":"Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996; 21: 39\u201350.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR51","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/BF02922260","volume":"247","author":"N M\u00fcller","year":"1997","unstructured":"M\u00fcller N, Empl M, Riedel M, Schwarz M, Ackenheil M . Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997; 247: 308\u2013313.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFmp20163_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.psychres.2007.11.014","volume":"160","author":"SM O\u2019Brien","year":"2008","unstructured":"O\u2019Brien SM, Scully P, Dinan TG . Increased tumor necrosis factor alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 2008; 160: 256\u2013262.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR53","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.intimp.2005.10.004","volume":"6","author":"CU Pae","year":"2006","unstructured":"Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 2006; 6: 666\u2013671.","journal-title":"Int Immunopharmacol"},{"key":"BFmp20163_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0447.1994.tb01599.x","volume":"90","author":"MH Rapaport","year":"1994","unstructured":"Rapaport MH, Lohr JB . Serum-soluble interleukin-2 receptors in neuroleptic-na\u00efve schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994; 90: 311\u2013315.","journal-title":"Acta Psychiatr Scand"},{"key":"BFmp20163_CR55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s004060050051","volume":"248","author":"MJ Schwarz","year":"1998","unstructured":"Schwarz MJ, Riedel M, Gruber R, Muller N, Ackenheil M . Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1998; 248: 282\u2013288.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFmp20163_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.psychres.2004.04.012","volume":"134","author":"P Sirota","year":"2005","unstructured":"Sirota P, Meiman M, Herschko R, Bessler H . Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 2005; 134: 151\u2013159.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR57","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","volume":"65","author":"XQ Song","year":"2009","unstructured":"Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP . The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 2009; 65: 481\u2013488.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.schres.2013.07.044","volume":"150","author":"X Song","year":"2013","unstructured":"Song X, Fan X, Song X, Zhang J, Zhang W, Li X et al. Elevated levels of adiponectin and other cytokines in drug na\u00efve first episode schizophrenia patients with normal weight. Schizophr Res 2013; 150: 269\u2013273.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00213-013-3382-4","volume":"231","author":"X Song","year":"2014","unstructured":"Song X, Fan X, Li X, Zhang W, Gao J, Zhao J et al. Changes in pro-inflammatory cytokines and body weight during 6-montth risperidone treatment in drug na\u00efve first-episode schizophrenia. Psychopharmacology 2014; 231: 319\u2013325.","journal-title":"Psychopharmacology"},{"key":"BFmp20163_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0920-9964(00)00007-4","volume":"47","author":"S Theodoropoulou","year":"2001","unstructured":"Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001; 47: 13\u201325.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2014.03.024","volume":"156","author":"MH Xiu","year":"2014","unstructured":"Xiu MH, Yang GG, Tan YL, Chen DC, Tan SP, Wag ZR et al. Decreased interleukin-10 serum levels in first-episode drug-na\u00efve schizophrenia: relationship to psychopathology. Schizophr Res 2014; 156: 9\u201314.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR62","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jpsychires.2012.04.026","volume":"46","author":"MH Xiu","year":"2012","unstructured":"Xiu MH, Chen DC, Wang D, Zhang K, Dong A, Tang W et al. Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology. J Psychiatr Res 2012; 46: 1093\u20131098.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2013.03.001","volume":"32","author":"XY Zhang","year":"2013","unstructured":"Zhang XY, Tang W, Xiu MH, Chen DC, Yang FD, Tan YL et al. Interleukin-18 and cognitive impairment in first episode and drug na\u00efve schizophrenia versus healthy controls. Brain Behav Immun 2013; 32: 105\u2013111.","journal-title":"Brain Behav Immun"},{"key":"BFmp20163_CR64","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jpsychires.2010.05.015","volume":"45","author":"F Kapczinski","year":"2011","unstructured":"Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PVS, Kauer-Sant\u2019Anna M, Flamt F et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156\u2013161.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.psychres.2004.08.005","volume":"129","author":"YK Kim","year":"2004","unstructured":"Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004; 129: 267\u2013272.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jad.2014.12.033","volume":"174","author":"H Li","year":"2015","unstructured":"Li H, Hong W, Zhang C, Wu Z, Wang Z, Yuan C et al. IL-23 and TGF-\u03b21 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord 2015; 174: 361\u2013366.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jneuroim.2004.01.006","volume":"150","author":"HC Liu","year":"2004","unstructured":"Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ . Immunological variables in acute mania of bipolar disorder. J Neuroimmunol 2004; 150: 116\u2013122.","journal-title":"J Neuroimmunol"},{"key":"BFmp20163_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbi.2014.09.021","volume":"43","author":"K Munkholm","year":"2014","unstructured":"Munkholm K, Weikop P, Kessing LV, Vinberg M . Elevated levels of IL-6 and IL-18 in manic hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun 2014; 43: 205\u2013213.","journal-title":"Brain Behav Immun"},{"key":"BFmp20163_CR69","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jad.2005.11.015","volume":"90","author":"SM O\u2019Brien","year":"2006","unstructured":"O\u2019Brien SM, Scully P, Scott LV, Dinan TG . Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263\u2013267.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR70","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0006-3223(98)00159-0","volume":"45","author":"SY Tsai","year":"1999","unstructured":"Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 1999; 45: 989\u2013994.","journal-title":"Biol Psychiatry"},{"key":"BFmp20163_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0165-0327(00)00252-4","volume":"64","author":"SY Tsai","year":"2001","unstructured":"Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJC . Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord 2001; 64: 185\u2013193.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR72","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0022-3956(02)00103-6","volume":"37","author":"SY Tsai","year":"2003","unstructured":"Tsai SY, Lee HC, Chen CC, Lee CH . Plasma levels of soluble transferrin receptors and clara cell protein (CC16) during bipolar mania and subsequent remission. J Psychiatr Res 2003; 37: 229\u2013235.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR73","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jad.2011.08.022","volume":"136","author":"SY Tsai","year":"2012","unstructured":"Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH . Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110\u2013116.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hup.717","volume":"20","author":"AD Basterzi","year":"2005","unstructured":"Basterzi AD, Avdemir C, Kisa C, Aksaray S, Tuzer V, Yazici K et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20: 473\u2013476.","journal-title":"Hum Psychopharmacol"},{"key":"BFmp20163_CR75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0022-3999(97)00139-6","volume":"43","author":"M Berk","year":"1997","unstructured":"Berk M, Wadee AA, Kuschke RH, O\u2019Neill-Kerr A . Acute phase proteins in major depression. J Psychosomat Res 1997; 43: 529\u2013534.","journal-title":"J Psychosomat Res"},{"key":"BFmp20163_CR76","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jad.2011.09.027","volume":"136","author":"P Dome","year":"2012","unstructured":"Dome P, Halmai Z, Dobos J, Lazary J, Gonda X, Kenessey I et al. Investigation of circulating endothelial progenitor cells and angiogenic and inflammatory cytokines during recovery from an episode of major depression. J Affect Disord 2012; 136: 1159\u20131163.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.pnpbp.2007.09.015","volume":"32","author":"T Eller","year":"2008","unstructured":"Eller T, Vaasar V, Shlik J, Maron E . Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 445\u2013450.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFmp20163_CR78","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jad.2012.08.007","volume":"145","author":"M Fornaro","year":"2013","unstructured":"Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M . Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J Affect Disord 2013; 145: 300\u2013307.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR79","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.euroneuro.2008.08.001","volume":"18","author":"ME Hernandez","year":"2008","unstructured":"Hernandez ME, Mendieta D, Martinez-Fong D, Loria F, Moreno J, Estrada I et al. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 917\u2013924.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFmp20163_CR80","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1440-1819.2007.01686.x","volume":"61","author":"TL Huang","year":"2007","unstructured":"Huang TL, Lee CT . T-helper 1\/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry Clin Neurosci 2007; 61: 415\u2013420.","journal-title":"Psychiatry Clin Neurosci"},{"key":"BFmp20163_CR81","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000054867","volume":"43","author":"A Kagaya","year":"2001","unstructured":"Kagaya A, Kugaya A, Takebayashi M, Fukue-Saeki M, Saeki T, Yamawaki S et al. Plasma concentrations on interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001; 43: 59\u201362.","journal-title":"Neuropsychobiology"},{"key":"BFmp20163_CR82","first-page":"237","volume":"52","author":"M Kubera","year":"2000","unstructured":"Kubera M, Kenis G, Bosans E, Zieba A, Dudek D, Mowak G et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Polish J Pharmacol 2000; 52: 237\u2013241.","journal-title":"Polish J Pharmacol"},{"key":"BFmp20163_CR83","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.intimp.2006.03.015","volume":"6","author":"K-M Lee","year":"2006","unstructured":"Lee K-M, Kim Y-K . The role of IL-12 and TGF-\u03b21 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006; 6: 1298\u20131304.","journal-title":"Int Immunopharmacol"},{"key":"BFmp20163_CR84","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.4088\/JCP.v67n1114","volume":"67","author":"R Leo","year":"2006","unstructured":"Leo R, DiLorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G et al. Association between enchanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006; 67: 1760\u20131766.","journal-title":"J Clin Psychiatry"},{"key":"BFmp20163_CR85","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0165-0327(95)00028-L","volume":"34","author":"M Maes","year":"1995","unstructured":"Maes M, Meltzer HY, Bosmans E, Bergmans R, Vadoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301\u2013309.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR86","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1006\/cyto.1997.0238","volume":"9","author":"M Maes","year":"1997","unstructured":"Maes M, Bosmans E, De Jongh R, Kenis G, Vadoolaeghe E, Neels H . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853\u2013858.","journal-title":"Cytokine"},{"key":"BFmp20163_CR87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0924-977X(01)00081-5","volume":"11","author":"O Mikova","year":"2001","unstructured":"Mikova O, Yakimova R, Bosmans, Kenis G, Maes M . Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001; 11: 203\u2013208.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFmp20163_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0165-1781(96)02783-7","volume":"64","author":"A Sluzewska","year":"1996","unstructured":"Sluzewska A, Rybakowski J, Bostmans E, Sobieska M, Berghmans R, Maes M et al. Indictors of immune activation in major depression. Psychiatry Res 1996; 64: 161\u2013167.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2190\/PM.42.3.a","volume":"42","author":"SC Su","year":"2011","unstructured":"Su SC, Sun MT, Wen MJ, Lin CH, Chen YC, Hung YJ . Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med 2011; 42: 211\u2013226.","journal-title":"Int J Psychiatry Med"},{"key":"BFmp20163_CR90","doi-asserted-by":"publisher","first-page":"76396","DOI":"10.1155\/2007\/76396","volume":"2007","author":"L Sutcigil","year":"2007","unstructured":"Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007; 2007: 76396.","journal-title":"Clin Dev Immunol"},{"key":"BFmp20163_CR91","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0960327113493305","volume":"33","author":"AK Al-Asmari","year":"2014","unstructured":"Al-Asmari AK, Khan MW . Inflammation and schizophrenia: Alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol 2014; 33: 115\u2013122.","journal-title":"Hum Exp Toxicol"},{"key":"BFmp20163_CR92","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.physbeh.2014.02.032","volume":"129","author":"E Asevedo","year":"2014","unstructured":"Asevedo E, Rizzo LB, Gadelha A, Mansur R, Ota VK, Berberian AA et al. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol Behav 2014; 129: 194\u2013198.","journal-title":"Physiol Behav"},{"key":"BFmp20163_CR93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881108089583","volume":"23","author":"S Barry","year":"2009","unstructured":"Barry S, Clarke G, Scully P, Dinan TG . Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 2009; 23: 287\u2013294.","journal-title":"J Psychopharmacol"},{"key":"BFmp20163_CR94","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.psyneuen.2012.04.001","volume":"37","author":"W Beumer","year":"2012","unstructured":"Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D . Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychneuroendocrinology 2012; 37: 1901\u20131911.","journal-title":"Psychneuroendocrinology"},{"key":"BFmp20163_CR95","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1017\/S1461145709000315","volume":"12","author":"C Bresee","year":"2009","unstructured":"Bresee C, Rapaport MH . Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 2009; 12: 861\u2013865.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFmp20163_CR96","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/pcn.12040","volume":"67","author":"SSW Chiang","year":"2013","unstructured":"Chiang SSW, Ridel M, Schwarz M, Muller N . Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. Psychiatry Clin Neurosci 2013; 67: 228\u2013236.","journal-title":"Psychiatry Clin Neurosci"},{"key":"BFmp20163_CR97","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.schres.2008.03.018","volume":"102","author":"RC Drexhage","year":"2008","unstructured":"Drexhage RC, Padmos RC, de Wit H, Versnel MA, Hooijkaas H, van der Lely AJ et al. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? Schizophr Res 2008; 102: 352\u2013355.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR98","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neulet.2011.06.042","volume":"502","author":"LP Francesconi","year":"2011","unstructured":"Francesconi LP, Cereser KM, Mascarenhas, Stertz L, Gama CS, Belmonte-de-Abreu P . Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neurosci Lett 2011; 502: 143\u2013146.","journal-title":"Neurosci Lett"},{"key":"BFmp20163_CR99","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.psychres.2012.11.020","volume":"209","author":"F-C Kuo","year":"2013","unstructured":"Kuo F-C, Lee C-H, Hsieh C-H, Kuo P, Chen Y-C, Hung Y-J . Lifestyle modification and behavior therapy effectively reduce body weight and increase serum level of brain-derived neurotrophic factor in obsess non-diabetic patients with schizophrenia. Psychiatry Res 2013; 209: 150\u2013154.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR100","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.psychres.2012.01.002","volume":"198","author":"H Liu","year":"2012","unstructured":"Liu H, Kang Y, Liang J, Li C, Xiu M, Chen D et al. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res 2012; 198: 329\u2013331.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR101","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jpsychires.2012.03.019","volume":"46","author":"M Pedrini","year":"2012","unstructured":"Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, JCP Moreira et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012; 46: 819\u2013824.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR102","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jpsychires.2011.06.003","volume":"45","author":"D Sasayama","year":"2011","unstructured":"Sasayama D, Wakabayash C, Hori H, Teraishi T, Hattori K, Ota M et al. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiatr Res 2011; 45: 1439\u20131444.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR103","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jpsychires.2012.12.001","volume":"47","author":"D Sasayama","year":"2013","unstructured":"Sasayama D, Hattori K, Wakabayash C, Teraishi T, Hori H, Ota M et al. Increased cerebrospinal fluid inteleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 2013; 47: 401\u2013406.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2009.05.005","volume":"47","author":"B Singh","year":"2009","unstructured":"Singh B, Bera NK, Nayak CR, Chaudhuri TK . Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009; 47: 1\u20135.","journal-title":"Cytokine"},{"key":"BFmp20163_CR105","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2013.12.005","volume":"41","author":"A Stojanovic","year":"2014","unstructured":"Stojanovic A, Martorell, Montalvo I, Ortega L, Monseny R, Vilella E et al. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychneuroendocrinology 2014; 41: 23\u201332.","journal-title":"Psychneuroendocrinology"},{"key":"BFmp20163_CR106","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.psychres.2011.07.006","volume":"189","author":"J Suvisaari","year":"2011","unstructured":"Suvisaari J, Loo BM, Saarni SE, Haukka J, Perala J, Saarni SI et al. Inflammation in psychotic disorders: a population-based study. Psychiatry Res 2011; 189: 305\u2013311.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR107","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2013.10.019","volume":"151","author":"DH Dimitrov","year":"2013","unstructured":"Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida N et al. Differential correlations between inflammatory cytokine sand psychopathology in veterans with schizophrenia: potential role for Il-17 pathway. Schizohpr Res 2013; 151: 29\u201335.","journal-title":"Schizohpr Res"},{"key":"BFmp20163_CR108","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jpsychires.2012.12.010","volume":"47","author":"C Noto","year":"2013","unstructured":"Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS et al. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J Psychiatr Res 2013; 47: 467\u2013471.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR109","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jad.2014.05.009","volume":"166","author":"YM Bai","year":"2014","unstructured":"Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T et al. Comparison of inflammatory cytokine levels among type I\/type II and manic\/hypomanic\/euthymic\/depressive states of bipolar disorder. J Affect Disord 2014; 166: 187\u2013192.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR110","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jpsychires.2011.11.010","volume":"46","author":"IG Barbosa","year":"2012","unstructured":"Barbosa IG, Rocha NP, de Miranda AS, Magalhaes PV, Huguet RB, de Souza LP et al. Increased levels of adipokines in bipolar. J Psychiatr Res 2012; 46: 389\u2013393.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR111","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.jpsychires.2013.08.019","volume":"47","author":"IG Barbosa","year":"2013","unstructured":"Barbosa IG, Nogueira CR, Rocha NP, Queiroz AL, Vago JP, Tavares LP et al. Altered intracellular signaling cascades in peripheral blood mononuclear celles from BD patients. J Psychiatr Res 2013; 47: 1949\u20131954.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR112","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.bbi.2009.04.008","volume":"23","author":"E Brietzke","year":"2009","unstructured":"Brietzke E, Kauer-Sant-Anna M, Teixeira AL, Kapczinski F . Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009; 23: 1079\u20131082.","journal-title":"Brain Behav Immun"},{"key":"BFmp20163_CR113","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1399-5618.2010.00822.x","volume":"12","author":"E Brietzke","year":"2010","unstructured":"Brietzke E, Teixeira AL . Similar immune profile in bipolar disorder and schizophrenia, selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2010; 12: 453\u2013454.","journal-title":"Bipolar Disord"},{"key":"BFmp20163_CR114","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-244X-12-158","volume":"12","author":"T Cetin","year":"2012","unstructured":"Cetin T, Guloksuz S, Cetin EA, Gazioglu SB, Deniz G, Oral ET et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar paitents with and without subsyndromal symptoms. BMC Psychiatry 2012; 12: 158.","journal-title":"BMC Psychiatry"},{"key":"BFmp20163_CR115","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hup.2301","volume":"28","author":"O Doganavsargil-Baysal","year":"2013","unstructured":"Doganavsargil-Baysal O, Cinemre B, Aksoy UM, Akbas H, Metin O, Fettahoglu C et al. Levels of TNF-\u03b1, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol 2013; 28: 160\u2013167.","journal-title":"Hum Psychopharmacol"},{"key":"BFmp20163_CR116","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jad.2010.04.027","volume":"126","author":"S Guloksuz","year":"2010","unstructured":"Guloksuz S, Cetin EA, Cetin T, Geniz G, Oral ET, Nutt DJ . Cytokine levels in euthymic bipolar patients. J Affect Disord 2010; 126: 458\u2013462.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR117","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jpsychires.2011.08.003","volume":"45","author":"S Hope","year":"2011","unstructured":"Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45: 1608\u20131616.","journal-title":"J Psychiatr Res"},{"key":"BFmp20163_CR118","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bdi.12164","volume":"16","author":"JW Hsu","year":"2014","unstructured":"Hsu JW, Lirng JF, Wang SJ, Lin CL, Yang KC, Liao MH et al. Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study. Bipolar Disord 2014; 16: 241\u2013248.","journal-title":"Bipolar Disord"},{"key":"BFmp20163_CR119","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/gps.4048","volume":"29","author":"FE Lotrich","year":"2014","unstructured":"Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds CF, Gildengers AG . The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2014; 29: 635\u2013644.","journal-title":"Int J Geriatr Psychiatry"},{"key":"BFmp20163_CR120","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.jpsychires.2013.08.020","volume":"47","author":"R Mota","year":"2013","unstructured":"Mota R, Gazal M, Acosta BA, de Leon PB, Jansen K, Pinheiro RT et al. Interleukin-1\u03b2 is associated with depressive episode in major depression but not in bipolar disorder. J Psychaitr Res 2013; 47: 2011\u20132014.","journal-title":"J Psychaitr Res"},{"key":"BFmp20163_CR121","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0165-0327(94)90012-4","volume":"32","author":"MH Rapaport","year":"1994","unstructured":"Rapaport MH . Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord 1994; 32: 149\u2013156.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR122","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000339949","volume":"66","author":"A Remlinger-Molenda","year":"2012","unstructured":"Remlinger-Molenda A, Wojciak P, Michalak M, Karczewski J, Rybakowski JK . Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology 2012; 66: 193\u2013198.","journal-title":"Neuropsychobiology"},{"key":"BFmp20163_CR123","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.plefa.2013.09.008","volume":"89","author":"D Baek","year":"2013","unstructured":"Baek D, Park Y . Association between erythrocyte n-3 polyunsaturated fatty acids and biomarkers of inflammation and oxidative stress in patients with and without depression. Prostaglandins Leukot Essent Fatty Acids 2013; 89: 291\u2013296.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BFmp20163_CR124","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jpsychires.2009.05.010","volume":"43","author":"FS Dhabhar","year":"2009","unstructured":"Dhabhar FS, Burke HM, Epel ES, Mellon SH, Rosser R, Reus VI et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatric Res 2009; 43: 962\u2013969.","journal-title":"J Psychiatric Res"},{"key":"BFmp20163_CR125","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/JGP.0b013e3181c2947f","volume":"18","author":"BS Diniz","year":"2010","unstructured":"Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV . Interleukin-1\u03b2 serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry 2010; 18: 172\u2013176.","journal-title":"Am J Geriatr Psychiatry"},{"key":"BFmp20163_CR126","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.genhosppsych.2012.01.017","volume":"34","author":"G Einvik","year":"2012","unstructured":"Einvik G, Vistnes M, Hrubos-Strom H, Randby A, Namtvedt SK, Nordhus IH et al. Circulating cytokine concentrations are no associated with major depressive disorder in a community-based cohort. Gen Hosp Psychiatry 2012; 34: 262\u2013267.","journal-title":"Gen Hosp Psychiatry"},{"key":"BFmp20163_CR127","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/medicina45120124","volume":"45","author":"T Eller","year":"2009","unstructured":"Eller T, Aluoja A, Maron E, Vasar V . Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina (Kaunas) 2009; 45: 971\u2013977.","journal-title":"Medicina (Kaunas)"},{"key":"BFmp20163_CR128","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jad.2011.11.016","volume":"136","author":"M Maes","year":"2012","unstructured":"Maes M, Ringel K, Kubera M, Berk M, Rybakowski J . Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012; 136: 386\u2013392.","journal-title":"J Affect Disord"},{"key":"BFmp20163_CR129","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.psy.0000149259.72488.09","volume":"67","author":"SJ Motovala","year":"2005","unstructured":"Motovala SJ, Sarfatti A, Olmos L, Irwin MR . Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005; 67: 187\u2013194.","journal-title":"Psychosom Med"},{"key":"BFmp20163_CR130","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jpsychires.2006.05.013","volume":"41","author":"SM O\u2019Brien","year":"2007","unstructured":"O\u2019Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG . Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatric Res 2007; 41: 326\u2013331.","journal-title":"J Psychiatric Res"},{"key":"BFmp20163_CR131","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jneuroim.2005.08.014","volume":"172","author":"L Pavon","year":"2006","unstructured":"Pavon L, Sandoval-Lopez G, Hernandez ME, Loria F, Estrada I, Perez M et al. Th2 cytokine response in major depressive disorder patients before treatment. J Neuroimmunol 2006; 172: 156\u2013165.","journal-title":"J Neuroimmunol"},{"key":"BFmp20163_CR132","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bbi.2005.05.004","volume":"20","author":"JL Pike","year":"2006","unstructured":"Pike JL, Irwin MR . Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 2006; 20: 169\u2013174.","journal-title":"Brain Behav Immun"},{"key":"BFmp20163_CR133","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.euroneuro.2007.06.004","volume":"18","author":"NM Simon","year":"2008","unstructured":"Simon NM, McNamara K, Chow CW, Maser RS, Papkostas GI, Pollack MH et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 230\u2013233.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFmp20163_CR134","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/hup.1155","volume":"25","author":"R Yoshimura","year":"2010","unstructured":"Yoshimura R, Umene-Nakano W, Hoshuyama T, Ikenouchi-Sugita A, Hori K, Katsuki A et al. Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls. Hum Psychopharmacol 2010; 25: 566\u2013569.","journal-title":"Hum Psychopharmacol"},{"key":"BFmp20163_CR135","doi-asserted-by":"publisher","first-page":"e99317","DOI":"10.1371\/journal.pone.0099317","volume":"9","author":"AV Hernandez","year":"2014","unstructured":"Hernandez AV, Guarnizo M, Miranda Y et al. Association between insulin resistance and breast carcinoma: a systematic review and meta-analysis. PLoS One 2014; 9: e99317.","journal-title":"PLoS One"},{"key":"BFmp20163_CR136","unstructured":"Higgins J, Deeks J Selecting studies and collecting data. Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011) The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org."},{"key":"BFmp20163_CR137","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/biomet\/37.3-4.256","volume":"37","author":"WB Cochran","year":"1950","unstructured":"Cochran WB . The comparison of percentages in matched samples. Biometrika 1950; 37: 256\u2013266.","journal-title":"Biometrika"},{"key":"BFmp20163_CR138","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/016327870102400203","volume":"24","author":"F Song","year":"2001","unstructured":"Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR . Methods for exploring heterogeneity in meta-analysis. Eval Health Prof 2001; 24: 126\u2013151.","journal-title":"Eval Health Prof"},{"key":"BFmp20163_CR139","unstructured":"Higgins JPT, Green S . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 9.7. Sensitivity analyses. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org."},{"key":"BFmp20163_CR140","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M . Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046\u20131055.","journal-title":"J Clin Epidemiol"},{"key":"BFmp20163_CR141","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629\u2013634.","journal-title":"BMJ"},{"key":"BFmp20163_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60740-3","volume":"65","author":"S Akira","year":"1997","unstructured":"Akira S, Kishimoto T . NF-IL6 and NF-kappa B in cytokine gene regulation. Adv Immunol 1997; 65: 1\u201346.","journal-title":"Adv Immunol"},{"key":"BFmp20163_CR143","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1749-6632.2009.04984.x","volume":"1179","author":"TW Pace","year":"2009","unstructured":"Pace TW, Miller AH . Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann NY Acad Sci 2009; 1179: 86\u2013105.","journal-title":"Ann NY Acad Sci"},{"key":"BFmp20163_CR144","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/ar1784","volume":"7","author":"R Thomas","year":"2005","unstructured":"Thomas R . The TRAF6-NF kappa B signaling pathway in autoimmunity: not just inflammation. Arthritis Res Ther 2005; 7: 170\u2013173.","journal-title":"Arthritis Res Ther"},{"key":"BFmp20163_CR145","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1016\/j.psyneuen.2013.06.026","volume":"38","author":"HM Derry","year":"2013","unstructured":"Derry HM, Fagundes CP, Andridge R, Glaser R, Malarkey WB, Kiecolt-Glaser JK . Lower subjective social status exaggerates interleukin-6 responses to a laboratory stressor. Psychoneuroendocrinology 2013; 38: 2676\u20132685.","journal-title":"Psychoneuroendocrinology"},{"key":"BFmp20163_CR146","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1037\/a0025536","volume":"31","author":"JP Gouin","year":"2012","unstructured":"Gouin JP, Glaser R, Malarkey WB, Beversdorf D, Kiecolt-Glaser J . Chronic stress, daily stressors, and circulating inflammatory markers. Health Psychol 2012; 31: 264\u2013268.","journal-title":"Health Psychol"},{"key":"BFmp20163_CR147","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/cyto.1997.0290","volume":"10","author":"M Maes","year":"1998","unstructured":"Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313\u2013318.","journal-title":"Cytokine"},{"key":"BFmp20163_CR148","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1176\/appi.ajp.160.9.1554","volume":"160","author":"CL Raison","year":"2003","unstructured":"Raison CL, Miller AH . When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554\u20131565.","journal-title":"Am J Psychiatry"},{"key":"BFmp20163_CR149","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbi.2006.03.005","volume":"21","author":"MG Frank","year":"2007","unstructured":"Frank MG, Baratta MV, Sprunger DB, Watkins LR, Maier SF . Microglia serve as a neuroendocrine substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Bran Behav Immun 2007; 21: 47\u201359.","journal-title":"Bran Behav Immun"},{"key":"BFmp20163_CR150","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA . IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448\u2013457.","journal-title":"Nat Immunol"},{"key":"BFmp20163_CR151","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.smim.2013.10.007","volume":"25","author":"P Piccioli","year":"2013","unstructured":"Piccioli P, Rubartelli A . The secretion of IL-1B and options for release. Semin Immunol 2013; 25: 425\u2013429.","journal-title":"Semin Immunol"},{"key":"BFmp20163_CR152","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1155\/S0962935193000018","volume":"2","author":"C Caruso","year":"1993","unstructured":"Caruso C, Candore G, Cigna D, Colucci AT, Modica MA . Biological significance of soluble IL-2 receptor. Mediat Inflamm 1993; 2: 3\u201321.","journal-title":"Mediat Inflamm"},{"key":"BFmp20163_CR153","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-2172-10-52","volume":"10","author":"W De Jager","year":"2009","unstructured":"De Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V . Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009; 10: 52.","journal-title":"BMC Immunol"},{"key":"BFmp20163_CR154","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ymeth.2013.04.005","volume":"61","author":"GC Keustermans","year":"2013","unstructured":"Keustermans GC, Hoeks SM, Meerding JM, Prakken BJ, de Jager W . Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods 2013; 61: 10\u201317.","journal-title":"Methods"},{"key":"BFmp20163_CR155","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/gerona\/63.8.879","volume":"63","author":"SX Leng","year":"2008","unstructured":"Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kechel GA . ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A 2008; 63: 879\u2013888.","journal-title":"J Gerontol A"},{"key":"BFmp20163_CR156","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.bbi.2009.04.005","volume":"23","author":"MF O\u2019Connor","year":"2009","unstructured":"O\u2019Connor MF, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun 2009; 23: 887\u2013897.","journal-title":"Brain Behav Immun"},{"key":"BFmp20163_CR157","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/039463201002300204","volume":"23","author":"D De Berardis","year":"2010","unstructured":"De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, Carano A et al. The effect of newer serotonin\u2013noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010; 23: 417\u2013422.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"BFmp20163_CR158","first-page":"129","volume":"59","author":"J M\u0142odzikowska-Albrecht","year":"2007","unstructured":"M\u0142odzikowska-Albrecht J, Steinborn B, Zarowski M . Cytokines, epilepsy and epileptic drugs\u2014is there a mutual influence? Pharmacol Rep 2007; 59: 129\u2013138.","journal-title":"Pharmacol Rep"},{"key":"BFmp20163_CR159","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11481-013-9516-y","volume":"9","author":"PB Raghavendra","year":"2014","unstructured":"Raghavendra PB, Lee E, Parameswaran N . Regulation of macrophage biology by lithium: a new look at an old drug. J Neuroimmune Pharmacol 2014; 9: 277\u2013284.","journal-title":"J Neuroimmune Pharmacol"},{"key":"BFmp20163_CR160","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","volume":"151","author":"V Tourjman","year":"2013","unstructured":"Tourjman V, Kouassi \u00c9, Kou\u00e9 M\u00c8, Rocchetti M, Fortin-Fournier S, Fusar-Poli P et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res 2013; 151: 43\u201347.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR161","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psychres.2014.04.049","volume":"218","author":"JP Klemettilia","year":"2014","unstructured":"Klemettilia JP, Kampman O, Seppala N, Viikki M, Hamalainen M, Moilanen E et al. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res 2014; 218: 277\u2013283.","journal-title":"Psychiatry Res"},{"key":"BFmp20163_CR162","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","volume":"54","author":"M Maes","year":"2002","unstructured":"Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Piolo R, Boin F et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002; 54: 281\u2013291.","journal-title":"Schizophr Res"},{"key":"BFmp20163_CR163","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","volume":"32","author":"A Lin","year":"1998","unstructured":"Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998; 32: 9\u201315.","journal-title":"Schizophr Res"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp20163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp20163","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp20163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:35:35Z","timestamp":1648766135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp20163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":163,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFmp20163"],"URL":"https:\/\/doi.org\/10.1038\/mp.2016.3","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]},"assertion":[{"value":"2 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Goldsmith has nothing to disclose relevant to the present work. In the past 12 months, Dr Goldsmith received grant funding from the Janssen Academic Research Mentoring program. Dr Goldsmith has also recieved training support from the National Institute of Mental Health (R25MH101079). Dr Rapaport has nothing to disclose relevant to the present work. In the past 12 months, Dr Rapaport is a member of the scientific advisory board for Pax (unpaid) and the Depression and Bipolar Alternative Therapies Foundation, and a consultant for the American Psychiatric Association. Dr Miller has nothing to disclose relevant to present work. In the past 12 months, Dr Miller has received grant support from the National Institute of Mental Health (1K23MH098014-01) and the American Psychiatric Association; Research support from the National Institutes of Health Clinical Loan Repayment Program and Georgia Regents University; Honoraria from Psychiatric Times; and Speaker fees for lectures from the University of Nevada, Reno and Emory University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}